Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease
https://doi.org/10.15829/1560-4071-2021-4676
Abstract
Due to the population aging and the accumulation of concomitant diseases, the prevalence of atrial fibrillation (AF) as the most common arrhythmia is increasing. On the other hand, 14% of the population has chronic kidney disease (CKD). These conditions are often combined with each other causing a prothrombogenic effect, which significantly increase the number of unfavorable outcomes such as thromboembolism, stroke, myocardial infarction and cardiovascular death. This is especially true for the last stages of CKD, the so-called end-stage renal disease with a glomerular filtration rate <29 ml/min/1,73 m2. Previously, the vitamin K antagonist warfarin was the central drug for anticoagulant therapy of AF + CKD combination, but in the last decade, direct oral anticoagulants became widely used. This article discusses the evidence base for using each of the anticoagulants in patients with AF+CKD combination compared with warfarin, including depending on the severity of glomerular filtration rate decrease.
About the Authors
N. Sh. Zagidullin
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa
Competing Interests:
Конфликт интересов не заявляется.
P. A. Davtyan
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa
Competing Interests:
Конфликт интересов не заявляется.
References
1. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021;42:5:373-498. doi:10.1093/eurheartj/ehaa612.
2. Levey AS. Defining AKD: The Spectrum of AKI, AKD, and CKD. Nephron. 2021;24:1-4. doi:10.1159/000516647.
3. Health NIo. (2010) United States Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
4. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572-86. doi:10.1038/ki.2011.223.
5. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125:2649-61. doi:10.1161/CIRCULATIONAHA.111.084996.
6. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J. Am. Soc. Nephrol. 2009;20:705-11. doi:10.1681/ASN.2007111207.
7. Soliman EZ, Prineas RJ, Go AS, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159:1102-7. doi:10.1016/j.ahj.2010.03.027.
8. Baber U, Howard VJ, Halperin l, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ. Arrhythm. Electrophysiol. 2011;4:26-32. doi:10.1161/CIRCEP.110.957100.
9. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-35. doi:10.1056/NEJMoa1105594.
10. Engelbertz P, Reinecke H. Atrial fibrillation and oral anticoagulation in chronic kidney disease. J Atrial Fib. 2012;4:89-100. doi:10.4022/jafib.445.
11. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009;2:33-7. doi:10.2147/ijnrd.s7781.
12. Ng KP, Edwards NC, Lip GY, et al. Atrial fibrillation in CKD: Balancing the risks and benefits of anticoagulation. Am J Kidney Dis. 2013;62:615-32. doi:10.1053/j.ajkd.2013.02.381.
13. Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, et al. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing Clin Electrophysiol. 2018;41:878. doi:10.1111/pace.13394.
14. Bonde AN, Lip GY, Kamper AL, et al. Net clinical beneft of antithrombotic therapy in patients with atrial fbrillation and chronic kidney disease. J Am Coll Cardiol. 2015;64:2471- 82. doi:10.1016/j.jacc.2014.09.051.
15. Friberg L, Benson L, Lip G. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015;36:297-306. doi:10.1093/eurheartj/ehu139.
16. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2599-604. doi:10.2215/CJN.02400311.
17. Jun M, James MT, Ma Z, et al. Alberta Kidney Disease Network. Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2017;69(6):734-43. doi:10.1053/j.ajkd.2016.10.018.
18. Dahal K, Kunwar S, Rijal J, et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016;149(4):951-9. doi:10.1378/chest.15-1719.
19. Limdi NA, Beasley TM, Baird MF, et al. Kidney function infuences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20:912-21. doi:10.1681/ASN.2008070802.
20. Reardon G, Nelson WW, Patel AA, et al. Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: Evidence of continuing low use despite consideration of stroke and bleeding risk. Drugs Aging. 2013;30:417-42. doi:10.1007/s40266-013-0067-y.
21. Yalamanchili V, Reilly RF. Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation? Semin Dial. 2011;24:387-8. doi:10.1111/j.1525-139X.2011.00885.x.
22. Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev. 2018;7:55-61. doi:10.15420/aer.2017.50.1.
23. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa1300615.
24. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-94. doi:10.1093/eurheartj/ehr342.
25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638.
26. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1056/NEJMoa1107039.
27. Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1;1(4):451- 60. doi:10.1001/jamacardio.2016.1170.
28. Godino C, Melillo F, Rubino F, et al. INSIghT investigators. Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Intern Emerg Med. 2019;14(8):1259-70. doi:10.1007/s11739-019-02100-9.
29. Feldberg J, Patel P, Farrell A, et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2019;1;34(2):265-77. doi:10.1093/ndt/gfy031.
30. Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-44. doi:10.1161/STROKEAHA.118.020232.
31. Peeters FECM, Dudink EAMP, Kimenai DM, et al. Vitamin K Antagonists, Non-Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation. TH Open. 2018;10;2(4):e391-e398. doi:10.1055/s-0038-1675578.
32. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018;138:1519-29. doi:10.1161/CIRCULATIONAHA.118.035418.
33. Herndon K, Guidry TJ, Wassell K, Elliott W. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital. Ann Pharmacother. 2020;54(6):554-60. doi:10.1177/1060028019897053.
34. Jang SM, Bahjri K, Tran H. Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Renal Impairment. Pharmacy (Basel). 2020;8(1):30. doi:10.3390/pharmacy8010030.
35. Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020;28:141(17):1384-92. doi:10.1161/CIRCULATIONAHA.119.044059.
36. Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. Int J Cardiol. 2017;231:162-9. doi:10.1016/j.ijcard.2016.11.303.
37. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665. Erratum in: Circulation. 2019;140(6):e285.
Supplementary files
Review
For citations:
Zagidullin N.Sh., Davtyan P.A. Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease. Russian Journal of Cardiology. 2021;26(3S):4676. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4676
Views:
11611
Email this article 